Nothing Special   »   [go: up one dir, main page]

BR112019008063A2 - anticorpos contra o vírus sincicial anti-respiratório e métodos de sua geração e uso - Google Patents

anticorpos contra o vírus sincicial anti-respiratório e métodos de sua geração e uso

Info

Publication number
BR112019008063A2
BR112019008063A2 BR112019008063A BR112019008063A BR112019008063A2 BR 112019008063 A2 BR112019008063 A2 BR 112019008063A2 BR 112019008063 A BR112019008063 A BR 112019008063A BR 112019008063 A BR112019008063 A BR 112019008063A BR 112019008063 A2 BR112019008063 A2 BR 112019008063A2
Authority
BR
Brazil
Prior art keywords
methods
generation
respiratory syncytial
syncytial virus
virus antibodies
Prior art date
Application number
BR112019008063A
Other languages
English (en)
Inventor
M Walker Laura
Original Assignee
Adimab Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adimab Llc filed Critical Adimab Llc
Publication of BR112019008063A2 publication Critical patent/BR112019008063A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

são fornecidos anticorpos anti-rsv com potência neutralizante contra o subtipo a de rsv e subtipo b de rsv, bem como métodos para sua identificação, isolamento, geração e métodos para sua preparação e uso.
BR112019008063A 2016-10-21 2017-10-20 anticorpos contra o vírus sincicial anti-respiratório e métodos de sua geração e uso BR112019008063A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662411500P 2016-10-21 2016-10-21
PCT/US2017/057720 WO2018075961A1 (en) 2016-10-21 2017-10-20 Anti-respiratory syncytial virus antibodies, and methods of their generation and use

Publications (1)

Publication Number Publication Date
BR112019008063A2 true BR112019008063A2 (pt) 2019-07-02

Family

ID=60263074

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019008063A BR112019008063A2 (pt) 2016-10-21 2017-10-20 anticorpos contra o vírus sincicial anti-respiratório e métodos de sua geração e uso

Country Status (12)

Country Link
US (2) US11312761B2 (pt)
EP (1) EP3528840A1 (pt)
JP (2) JP2020503844A (pt)
KR (1) KR102695416B1 (pt)
CN (1) CN110035771B (pt)
AU (1) AU2017345759B2 (pt)
BR (1) BR112019008063A2 (pt)
CA (1) CA3040886A1 (pt)
IL (3) IL303833A (pt)
MX (1) MX2019004448A (pt)
SG (1) SG11201903287PA (pt)
WO (1) WO2018075961A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3040886A1 (en) 2016-10-21 2018-04-26 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
JP7265984B2 (ja) 2016-10-21 2023-04-27 アディマブ， エルエルシー 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法
WO2018075974A2 (en) 2016-10-21 2018-04-26 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
MX2021007589A (es) * 2018-12-21 2021-12-10 23Andme Inc Anticuerpos anti il-36 y procedimientos de uso de estos.
WO2021138409A2 (en) * 2019-12-31 2021-07-08 Medstar Health, Inc. Anti-cd160 binding molecules for treating diseases
CN111172195A (zh) * 2020-02-13 2020-05-19 翁炳焕 一种新冠肺炎基因治疗制品的制备方法
KR102467943B1 (ko) * 2020-06-25 2022-11-16 재단법인 목암생명과학연구소 항-rsv 항체 및 이를 포함하는 약학적 조성물
CN112048006B (zh) * 2020-09-08 2021-04-27 扬州大学 一种替代中和效力测定的elisa方法及其应用
JP2023552846A (ja) * 2020-12-08 2023-12-19 フマブス バイオメッド エスアー メタニューモウイルスのｆ－タンパク質に結合する抗体およびその使用
AU2021399453A1 (en) * 2020-12-18 2023-07-27 Zhuhai Trinomab Pharmaceutical Co., Ltd. Respiratory syncytial virus-specific binding molecule
WO2022170126A2 (en) * 2021-02-05 2022-08-11 Adagio Therapeutics, Inc. Compounds specific to coronavirus s protein and uses thereof
CN118159556A (zh) * 2021-08-25 2024-06-07 甘李药业股份有限公司 抗rsv病毒抗体及其应用
WO2024141063A1 (zh) * 2022-12-30 2024-07-04 甘李药业股份有限公司 抗rsv病毒抗体、组合物、制剂及其应用
WO2024259075A1 (en) * 2023-06-14 2024-12-19 Tether Therapeutics, Inc. Polymer formulations for delivery of polynucleotides
WO2025015321A1 (en) * 2023-07-13 2025-01-16 Vir Biotechnology, Inc. Broadly neutralizing antibodies against rsv and mpv paramyxoviruses

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5824307A (en) 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
US5762905A (en) 1992-09-16 1998-06-09 The Scripps Research Institute Human neutralizing monoclonal antibodies to respiratory syncytial virus
AU689489B2 (en) 1993-07-30 1998-04-02 Oravax, Inc Monoclonal IgA antibody against respiratory syncytial virus
US5811524A (en) 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
WO1997010846A1 (en) 1995-09-18 1997-03-27 Intracel Corporation Neutralizing monoclonal antibodies to respiratory syncytial virus
US20020141990A1 (en) 1996-11-01 2002-10-03 Smithkline Beecham Corporation Anti-RSV human monoclonal antibodies
IL149085A0 (en) 1999-10-29 2002-11-10 Inhale Therapeutic Syst A dry powder composition containing a di or tripeptide
CA2398466A1 (en) 2000-01-27 2001-08-02 Medimmune, Inc. Ultra high affinity neutralizing antibodies
US7229619B1 (en) 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
CA2401652A1 (en) 2000-03-01 2001-09-07 Medimmune, Inc. High potency recombinant antibodies and method for producing them
US6565849B2 (en) 2000-03-02 2003-05-20 Medimmune, Inc. Methods of enhancing activity of vaccines and vaccine compositions
AU2001261137B2 (en) 2000-05-03 2006-05-25 Medimmune, Llc Combination therapy of respiratory diseases using antibodies and anti-inflammatory agents
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6818216B2 (en) 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
US7179900B2 (en) 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6855493B2 (en) 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
ATE489395T1 (de) 2000-12-12 2010-12-15 Medimmune Llc Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
WO2004091499A2 (en) 2003-04-09 2004-10-28 Neose Technologies, Inc. Intracellular formation of peptide conjugates
CA2522007A1 (en) 2003-04-11 2004-10-28 Medimmune, Inc. Methods of preventing or treating respiratory conditions
US7070786B2 (en) 2003-06-06 2006-07-04 Centocor, Inc. RSV proteins, antibodies, compositions, methods and uses
JP5848861B2 (ja) 2004-04-20 2016-01-27 ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ Ｃｄ２０に対するヒトモノクローナル抗体
JP2008513540A (ja) 2004-09-21 2008-05-01 メディミューン，インコーポレーテッド 呼吸器合胞体ウイルスに対する抗体及び該ウイルス用のワクチンを製造する方法
US7786273B2 (en) 2005-03-14 2010-08-31 Medimmune, Llc Macromolecules comprising a thioether cross-link
EP2450377A1 (en) 2006-09-07 2012-05-09 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus H5N1 and uses thereof
DE102006060799A1 (de) * 2006-12-21 2008-06-26 RUHR-UNIVERSITäT BOCHUM RSV F-Protein und seine Verwendung
WO2008106980A2 (en) 2007-03-06 2008-09-12 Symphogen A/S Recombinant antibodies for treatment of respiratory syncytial virus infections
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
CN101821289A (zh) * 2007-09-07 2010-09-01 西福根有限公司 重组制造抗rsv抗体的方法
WO2009042589A1 (en) 2007-09-24 2009-04-02 Vanderbilt University Monoclonal antibodies to respiratory syncytial virus and uses thereof
KR100938998B1 (ko) 2008-01-08 2010-01-28 (주) 에이프로젠 호흡기 신시티움 바이러스에 대한 항체
JP5575377B2 (ja) 2008-07-18 2014-08-20 シスメックス株式会社 抗ｒｓウイルスモノクローナル抗体を用いたｒｓウイルス検出用キット及びイムノクロマトグラフィー用試験具、並びに新規な抗ｒｓウイルスモノクローナル抗体
EP2387583B1 (en) 2009-01-14 2018-09-19 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
EP2438087B1 (en) 2009-06-05 2017-05-10 Ablynx N.V. Trivalent anti human respiratory syncytial virus (hrsv) nanobody constructs for the prevention and/or treatment of respiratory tract infections
SG178335A1 (en) * 2009-08-13 2012-03-29 Crucell Holland Bv Antibodies against human respiratory syncytial virus (rsv) and methods of use
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
WO2011050168A2 (en) 2009-10-21 2011-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Rsv immunogens, antibodies and compositions thereof
KR101896124B1 (ko) 2010-07-09 2018-09-07 얀센 백신스 앤드 프리벤션 비.브이. 항-인간 호흡기 세포융합 바이러스(ｒｓｖ) 항체 및 사용 방법
PL2950886T3 (pl) 2013-02-01 2020-06-01 Medimmune, Llc Epitopy białka F syncytialnego wirusa oddechowego
TWI659968B (zh) * 2013-03-14 2019-05-21 再生元醫藥公司 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法
US9856313B2 (en) * 2013-03-15 2018-01-02 Xiamen University Epitope of RSV fusion protein and antibody recognizing the same
EP2991679A4 (en) 2013-04-29 2016-12-07 Adimab Llc POLYSPECIFIC REAGENTS, PROCESS FOR THEIR PREPARATION AND USE
CN104293741A (zh) * 2014-10-10 2015-01-21 武汉大学 一种呼吸道合胞病毒病毒样颗粒疫苗及其制备方法和应用
CN107405397B (zh) 2014-10-27 2020-08-25 新加坡科技研究局 抗tim-3抗体
US10713731B2 (en) 2016-07-22 2020-07-14 Nec Corporation Method for secure ledger distribution and computer system using secure distributed ledger technology
CA3040886A1 (en) 2016-10-21 2018-04-26 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
WO2018075974A2 (en) 2016-10-21 2018-04-26 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
JP7265984B2 (ja) 2016-10-21 2023-04-27 アディマブ， エルエルシー 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法

Also Published As

Publication number Publication date
IL303833A (en) 2023-08-01
US12116401B2 (en) 2024-10-15
US11312761B2 (en) 2022-04-26
MX2019004448A (es) 2019-08-14
CA3040886A1 (en) 2018-04-26
IL293585A (en) 2022-08-01
KR102695416B1 (ko) 2024-08-13
US20190256581A1 (en) 2019-08-22
KR20190103147A (ko) 2019-09-04
CN110035771B (zh) 2024-03-08
CN110035771A (zh) 2019-07-19
WO2018075961A1 (en) 2018-04-26
RU2019115249A3 (pt) 2021-02-01
IL266101A (en) 2019-06-30
US20220144922A1 (en) 2022-05-12
RU2019115249A (ru) 2020-11-24
JP2022028898A (ja) 2022-02-16
EP3528840A1 (en) 2019-08-28
IL293585B2 (en) 2023-11-01
AU2017345759A1 (en) 2019-05-23
JP2020503844A (ja) 2020-02-06
NZ753071A (en) 2024-04-26
SG11201903287PA (en) 2019-05-30
AU2017345759B2 (en) 2024-06-20
JP7524155B2 (ja) 2024-07-29
IL293585B1 (en) 2023-07-01

Similar Documents

Publication Publication Date Title
BR112019008063A2 (pt) anticorpos contra o vírus sincicial anti-respiratório e métodos de sua geração e uso
EP3974447A3 (en) Anti-respiratory syncytial virus antibodies, and methods of their generation and use
EP3695003A4 (en) ANTIBODIES TO RESPIRATORY SYNCYTIAL VIRUS AND METHOD OF GENERATING AND USING THEREOF
PE20181530A1 (es) Vacuna de virus sincitial respiratorio
CL2016002455A1 (es) Anticuerpos multiespecíficos.
MY195681A (en) Aqueous Pharmaceutical Formulation Comprising Anti-Pd-L1 Antibody Avelumab
CL2015003655A1 (es) Polipéptidos f de prefusión del virus sincicial respiratorio (rsv) solubles y estabilizados
MX2021002168A (es) Compuestos antivirales.
MY192714A (en) Antibody neutralizing human respiratory syncytial virus
PH12018501094A1 (en) Process for the preparation of an apoptosis-inducing agent
CY1124521T1 (el) Σκευασματα αντισωματος anti-cd19
MX340786B (es) Sistema de arreglo termico.
BR112016013562A2 (pt) Anticorpos anti-tau(ps422) humanizados, seus usos, e formulações farmacêuticas
WO2018075954A3 (en) Anti-respiratory syncytial virus antibodies, and methods of their generation and use
BR112017003242A2 (pt) composto, métodos para tratar infecção por vírus e para fabricação de um medicamento, composição farmacêutica, e, uso de um composto.
ECSP18074962A (es) Derivados de aminotiazol útiles como agentes antivíricos
BR112016009757A8 (pt) “inibidores do vírus sincicial respiratório com base em quinazolina”
EA201891391A1 (ru) Диастереоселективный синтез фосфатных производных и пролекарства гемцитабина nuc-1031
BR112018014355A2 (pt) processos para a preparação de f-benzoxazinorifamicina i e para a preparação de 2-amino-5-fluorobenzeno-1,3-diol iii
EA201992027A1 (ru) Водный состав антитела против pd-l1
WO2018118754A8 (en) Antibodies to human respiratory syncytial virus protein f pre-fusion conformation and methods of use therefor
CL2017002255A1 (es) Procesos para preparar fluorocetólidos.
EA201991319A1 (ru) Вакцины аттенуированного свиного гриппа и способы их изготовления и применения
DOP2017000264A (es) Metodo para crear un compuesto a base de mercurio, compuesto a base de mercurio, metodos de uso del compuesto a base de mercurio y usos del compuesto a base de mercurio
UY34840A (es) Vacuna de virus de schmallenberg (sbv), métodos de producción y sus usos

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]